These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 1733552)
1. A clinical and pharmacological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue. McKeage M; Dady P; Clear M; MacDonald A Cancer Chemother Pharmacol; 1992; 29(3):201-6. PubMed ID: 1733552 [TBL] [Abstract][Full Text] [Related]
2. A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. Adkins DR; Irvin R; Kuhn J; Boldt DH; Roodman GD; Salzman D; Freytes C; Von Hoff DD; LeMaistre CF Invest New Drugs; 1993; 11(2-3):169-79. PubMed ID: 8262729 [TBL] [Abstract][Full Text] [Related]
3. Relationship between the pharmacokinetics and toxicity of mitozolomide. Kerr DJ; Slack JA; Secrett P; Stevens MF; Blackledge GR; Bradley C; Kaye SB Cancer Chemother Pharmacol; 1990; 25(5):352-4. PubMed ID: 2306796 [TBL] [Abstract][Full Text] [Related]
4. Phase I study of mitozolomide on a once daily for 5 days schedule. Schornagel JH; Simonetti G; Dubbelman R; ten Bokkel Huinink WW; McVie JG Cancer Chemother Pharmacol; 1990; 26(3):237-8. PubMed ID: 2357772 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of high-dose etoposide after short-term infusion. Köhl P; Köppler H; Schmidt L; Fritsch HW; Holz J; Pflüger KH; Jungclas H Cancer Chemother Pharmacol; 1992; 29(4):316-20. PubMed ID: 1537079 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and toxicity of two schedules of high dose epirubicin. Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173 [TBL] [Abstract][Full Text] [Related]
15. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Rasschaert M; Schrijvers D; Van den Brande J; Dyck J; Bosmans J; Merkle K; Vermorken JB Anticancer Drugs; 2007 Jun; 18(5):587-95. PubMed ID: 17414628 [TBL] [Abstract][Full Text] [Related]
16. Phase I trial of temozolomide using an extended continuous oral schedule. Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665 [TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of high-dose mitomycin C. Schilcher RB; Young JD; Ratanatharathorn V; Karanes C; Baker LH Cancer Chemother Pharmacol; 1984; 13(3):186-90. PubMed ID: 6386213 [TBL] [Abstract][Full Text] [Related]
18. Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. Choi KE; Ratain MJ; Williams SF; Golick JA; Beschorner JC; Fullem LJ; Bitran JD Cancer Res; 1989 Mar; 49(5):1318-21. PubMed ID: 2645050 [TBL] [Abstract][Full Text] [Related]
19. Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Politi PM; Xie F; Dahut W; Ford H; Kelley JA; Bastian A; Setser A; Allegra CJ; Chen AP; Hamilton JM Cancer Chemother Pharmacol; 1995; 36(6):513-23. PubMed ID: 7554044 [TBL] [Abstract][Full Text] [Related]
20. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. Shea TC; Flaherty M; Elias A; Eder JP; Antman K; Begg C; Schnipper L; Frei E; Henner WD J Clin Oncol; 1989 May; 7(5):651-61. PubMed ID: 2651580 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]